Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson’s Disease-Related Toxicity in Human Neurons
datasetposted on 21.10.2011, 00:00 authored by Nigel Ramsden, Jessica Perrin, Zhao Ren, Byoung Dae Lee, Nico Zinn, Valina L. Dawson, Danny Tam, Michael Bova, Manja Lang, Gerard Drewes, Marcus Bantscheff, Frederique Bard, Ted M. Dawson, Carsten Hopf
Leucine-rich repeat kinase-2 (LRRK2) mutations are the most important cause of familial Parkinson’s disease, and non-selective inhibitors are protective in rodent disease models. Because of their poor potency and selectivity, the neuroprotective mechanism of these tool compounds has remained elusive so far, and it is still unknown whether selective LRRK2 inhibition can attenuate mutant LRRK2-dependent toxicity in human neurons. Here, we employ a chemoproteomics strategy to identify potent, selective, and metabolically stable LRRK2 inhibitors. We demonstrate that CZC-25146 prevents mutant LRRK2-induced injury of cultured rodent and human neurons with mid-nanomolar potency. These precise chemical probes further validate this emerging therapeutic strategy. They will enable more detailed studies of LRRK2-dependent signaling and pathogenesis and accelerate drug discovery.